{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:48:58Z","timestamp":1787161738093,"version":"build-2736575974"},"reference-count":6,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1177\/00048674231174171","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:12:12Z","timestamp":1683727932000},"page":"933-934","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["The down-scheduling of MDMA and psilocybin(e): Too fast and too soon"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"first","affiliation":[{"name":"Metro South Mental Health, Woolloongabba, QLD, Australia"},{"name":"Princess Alexandra Hospital, School of Medicine, The University of Queensland, Woolloongabba, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"bibr1-00048674231174171","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"bibr2-00048674231174171","doi-asserted-by":"publisher","DOI":"10.1111\/anoc.12154"},{"key":"bibr3-00048674231174171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"bibr4-00048674231174171","volume-title":"An Evaluation of the Therapeutic Value, Benefits and Risks of Methylenedioxymethamphetamine (MDMA) and Psilocybin for the Treatment of Mental, Behavioural or Developmental Disorders: A Report to the Therapeutic Goods Administration","author":"Kisely S","year":"2021"},{"key":"bibr5-00048674231174171","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221083868"},{"key":"bibr6-00048674231174171","volume-title":"Notice of Final Decisions to Amend (Or Not Amend) the Current Poisons Standard in Relation to Psilocybine and MDMA","author":"Therapeutic Goods Administration","year":"2023"}],"container-title":["Australian & New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674231174171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674231174171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674231174171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:57:17Z","timestamp":1777373837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674231174171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/00048674231174171"],"URL":"https:\/\/doi.org\/10.1177\/00048674231174171","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}